Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women

References

• Wu T, Buck G. Side effects and discontinuation rates of intrauterine contraceptive devices use in the Jilin Province of China [J]. Asia Pac J Pubic Health. 1998; 10(1)33–8
   PubMedGoogle Scholar
• Stanback J, Grimes D. Can intrauterine device removals for bleeding or pain be predicted at a one-month follow-up visit? A multivariate analysis. Contraception. 1998; 58(6)357–60
   PubMed Web of Science ®Google Scholar
• Rivera R, Chen-Mok M, McMullen S. Analysis of client characteristics that may affect early discontinuation of the TCu-380A IUD. Contraception. 1999; 60(3)155–60
   PubMed Web of Science ®Google Scholar
• Petta CA, Faundes D, Pimentel E, Diaz J, Bahamondes L. The use of vaginal ultrasound to identify copper T IUDs at high risk of expulsion. Contraception. 1996; 54(5)287–9
   PubMed Web of Science ®Google Scholar
• Batar I, Kuukankorpi A, Siljander M, Elomaa K, Rauramo I. Five-year clinical experiences with NOVA T 380 copper IUD. Contraception. 2002; 66(5)309–14
   PubMed Web of Science ®Google Scholar
• Neuteboom K, de Kroon CD, Dersjant-Roorda M, Jansen FW. Follow-up visits after IUD-insertion: sense or nosense? A technology assessment study to analyze the effectiveness of follow-up visits after insertion. Contraception. 2003; 68(2)101–4
   PubMed Web of Science ®Google Scholar
• Colli E, Tong D, Penhallegon R, Parazzini F. Reasons for contraceptive discontinuation in women 20–39 years old in New Zealand. Contraception. 1999; 59(4)227–31
   PubMed Web of Science ®Google Scholar
• Hefnawi F, Saleh A, Kandil O, El-Sheikha Z, Hassanein M, Askalani H. Fibrinolytic activity of menstrual blood in normal and menorrhagic women and in women wearing the Lippes Loop and the Cu-T (200). Int J Gynaecol Obstet. 1979; 16(5)400–7
   PubMedGoogle Scholar
• Shaw ST, Macaulay LK, Sun NC, Tanaka MS, Roche PC. Changes of plasminogen activator in human uterine tissue induced by intrauterine contraceptive devices. Contraception. 1983; 27(2)131–40
   PubMed Web of Science ®Google Scholar
• Zhang PC, Fan RQ, Chen XM. Changes of peroxidase, plasminogen and fibrinolytic activity on menorrhagia induced by IUDS and the effect of treatment with vitamin E. Shengzhi Yu Biyun. 1987; 7(3)59–61
   PubMedGoogle Scholar
• Lethaby, A, Farquhar, C, Cooke, I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; (4):CD000249.
   Google Scholar
• Ewenstein BM. The pathophysiology of bleeding disorders presenting as abnormal uterine bleeding. Am J Obstet Gynecol 1996; 175(3 Pt 2)770–7
   PubMed Web of Science ®Google Scholar
• Wellington K, Wagstaff AJ. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs. 2003; 63(13)1417–33
   PubMed Web of Science ®Google Scholar
• Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol. 1991; 164(3)879–83
   PubMed Web of Science ®Google Scholar
• Preston JT, Cameron IT, Adams EJ, Smith SK. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol. 1995; 102(5)401–6
   PubMedGoogle Scholar
• Nilsson L, Rybo G. Treatment of menorrhagia with an antifibrinolytic agent, tranexamic acid. Acta Obstet Gynecol Scand. 1967; 46: 572–80
   Web of Science ®Google Scholar
• Vermylen J, Verhaegen-Declercq ML, Verstraete M, Fierens F. A double blind study of the effect of tranexamic acid in essential menorrhagia. Thromb Diath Haemorrh. 1968; 20(3)583–7
   PubMedGoogle Scholar
• Ylikorkala O, Viinikka L. Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. Br J Obstet Gynecol. 1983; 90(1)78–83
   PubMedGoogle Scholar
• Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ. 1996; 313(7057)579–82
   PubMed Web of Science ®Google Scholar
• Westrom L, Bengtsson LP. Effect of tranexamic acid (AMCA) in menorrhagia with intrauterine contraceptive devices. J Reprod Med. 1970; 5(4)41–8
   PubMed Web of Science ®Google Scholar
• Rivera R, Wheeler RG, Balogh SA, Hernandez AB, Arreola M. Sustained intrauterine release of AMCA to reduce menstrual blood loss. Contracept Deliv Syst. 1984; 5(2)109–15
   PubMedGoogle Scholar
• Ragab MI, Thomas MN. The use of tranexamic acid (AMCA) in IUDs as an anti-bleeding agent. Int J Gynaecol Obstet. 1976; 14(2)137–41
   PubMedGoogle Scholar
• Reid PC, Coker A, Coltart R. Assessment of menstrual blood loss using a pictorial chart: a validation study. BJOG. 2000; 107(3)320–2
   PubMed Web of Science ®Google Scholar
• Janssen CA, Scholten PC, Heintz AP. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol. 1995; 85(6)977–82
   PubMed Web of Science ®Google Scholar
• Hallberg L, Nilsson L. Determination of menstrual blood loss. Scand J Clin Lab Invest. 1964; 16: 244–8
   PubMed Web of Science ®Google Scholar